Alberto
Cordero Fort
Publications by the researcher in collaboration with Alberto Cordero Fort (37)
2024
-
Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty
Angiology, Vol. 75, Núm. 2, pp. 175-181
2023
-
Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342
-
Remnant cholesterol in patients admitted for acute coronary syndromes
European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 340-348
-
The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events
Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611
2022
-
Clinical and therapeutic characterization of the ischemic cardiopathy in Spain. Importance of cardiac rehabilitation programs
Medicina Clinica Practica, Vol. 5, Núm. 3
-
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry
European Journal of Clinical Investigation, Vol. 52, Núm. 12
-
Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252
-
Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials
American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575
-
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529
-
Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?
Acta Diabetologica, Vol. 59, Núm. 2, pp. 163-170
-
The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study
International Journal of Cardiology, Vol. 361, pp. 116-123
2021
-
Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events
Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169
-
Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
-
Mortality associated with cardiovascular disease in patients with COVID-19
REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38
-
Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
2020
-
Early revascularization and long-term mortality in high-risk patients with non–ST-elevation myocardial infarction. The CARDIOCHUS-HUSJ registry
Revista Espanola de Cardiologia, Vol. 73, Núm. 1, pp. 35-42
-
Long-term bleeding risk vs. mortality risk in acute coronary syndrome patients according to the 2019 ARC-HBR definition
Thrombosis Research
2019
-
Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors
Revista Espanola de Cardiologia
-
Incidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndrome
International Journal of Cardiology, Vol. 276, pp. 20-25
2018
-
Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings
Revista Espanola de Cardiologia, Vol. 71, Núm. 10, pp. 820-828